NASDAQ:CHMA
Delisted
Chiasma Stock News
$3.76
+0 (+0%)
At Close: May 27, 2022
Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results
08:00am, Friday, 20'th Nov 2020
NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize ora
91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial
Chiasma to Participate in the Jefferies Virtual London Healthcare Conference
08:00am, Monday, 16'th Nov 2020
NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize ora
Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript
02:52am, Sunday, 08'th Nov 2020
Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript
Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update
04:05pm, Thursday, 05'th Nov 2020
L aunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September
Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day
08:00am, Friday, 30'th Oct 2020
NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to p
Chiasma to Report Third Quarter 2020 Results on November 5
08:00am, Thursday, 29'th Oct 2020
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Oct 06, 2020 (Heraldkeepers) --
Orphan Drugs Market Insight The global orphan drugs market 2020 is set to nurture with towering value by the year 2023, as...
Crinetics Pharmaceuticals- Superior Molecules In Endocrinology
01:35pm, Tuesday, 01'st Sep 2020
Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.
Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?
06:01pm, Monday, 17'th Aug 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to red
Chiasma (CHMA) Q2 2020 Earnings Call Transcript
06:30am, Tuesday, 11'th Aug 2020
Except as required by law, Chiasma disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise. J
Strongbridge Biopharma's Recorlev Phase 3 Topline Data Due September 2020 Is A Major Value Inflection Point (NASDAQ:SBBP)
10:35pm, Monday, 10'th Aug 2020
Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows.
Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness
08:05pm, Monday, 10'th Aug 2020
MYCAPSSA® U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarterCompany to host conference call today, August 10, at 5pm
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
